Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055952 · ClinicalTrials.gov registry record · Phase 2
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00055952 is a Phase 2 study that has completed, run by Daiichi Sankyo.
The verdict
NCT00055952, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have relapsed or refractory Ewing's sarcoma or peripheral primitive neuroectodermal tumor or desmoplastic small round cell tumor.
Interventions
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055952
The ClinicalTrials.gov registry entry for NCT00055952 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00055952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055952 about?
NCT00055952 is a clinical study titled "Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have relapsed or refractory Ewing's sarcoma or peripheral primitive neuroectoderma...
What is the current status of trial NCT00055952?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00055952?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00055952?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.